undamentalytics Newsletter
Sign in

Wave Life Sciences, Inc. balance sheet

At the end of fiscal 2025, Wave Life Sciences, Inc. had total assets of $638m, total liabilities of $112m and shareholders' equity of $518m. It held $602m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents16115014317514718415188200302602197
Receivables——1102030——211112
Total current assets16115215020218523016399235320615459
Total assets165165182296284279207146275352638508
Accounts payable3581391471713161619
Deferred revenue (current)—311019092373215066449
Total current liabilities4121813011812164721861119555
Total debt000000000000
Total liabilities42234215213189167184227135112106
Shareholders' equity15313514073648332−4540210518402
Non-controlling interests and other (assets − liabilities − equity)8888888888——
Shares outstanding—24m28m29m34m49m60m87m119m153m—197m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: VRDN vs WVECGEN vs WVERXRX vs WVECYTK vs WVE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Wave Life Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Wave Life Sciences, Inc.